This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Migasena, S Articles by Losonsky, G Search for Related Content PubMed PubMed Citation Articles by Migasena, S Articles by Losonsky, G

Next Article 

Infect Immun. 1989 November; 57(11): 3261-3264

Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.

Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

ABSTRACT

A single dose (5 x 10(8) organisms) of attenuated A- B+ Vibrio cholerae classical Inaba recombinant vaccine strain CVD 103-HgR or placebo was administered to 24 healthy young Thai adults in a randomized, placebo-controlled, double-blind trial of safety and immunogenicity. None of the volunteers experienced untoward reactions. The vaccine strain was recovered from 2 of 12 vaccines. The vibriocidal antibody response (the best immunological correlate of protection) was good: 11 of 12 vaccinees (92%) manifested significant serotype-homologous Inaba antibody rises with a peak reciprocal geometric mean titer (RGMT) postvaccination of 3,417; 9 of 12 exhibited significant serotype-heterologous Ogawa antibody rises (prevaccination RGMT, 180; peak RGMT, 2,874). Nine of 12 vaccinees had significant rises in serum antitoxin. None of the controls exhibited rises in vibriocidal or antitoxic antibody. This preliminary study further confirms the safety and immunogenicity of CVD 103-HgR live oral cholera vaccine and paves the way for larger community studies of this candidate cholera vaccine.

This article has been cited by other articles:

• Stokes, N. R., Zhou, X., Meltzer, S. J., Kaper, J. B. (2004). Transcriptional Responses of Intestinal Epithelial Cells to Infection with Vibrio cholerae. Infect. Immun. 72: 4240-4248 [Abstract] [Full Text]  
• Tacket, C. O., Cohen, M. B., Wasserman, S. S., Losonsky, G., Livio, S., Kotloff, K., Edelman, R., Kaper, J. B., Cryz, S. J., Giannella, R. A., Schiff, G., Levine, M. M. (1999). Randomized, Double-Blind, Placebo-Controlled, Multicentered Trial of the Efficacy of a Single Dose of Live Oral Cholera Vaccine CVD 103-HgR in Preventing Cholera following Challenge with Vibrio cholerae O1 El Tor Inaba Three Months after Vaccination. Infect. Immun. 67: 6341-6345 [Abstract] [Full Text]  
• Gupta, R. K., Taylor, D. N., Bryla, D. A., Robbins, J. B., Szu, S. C. (1998). Phase 1 Evaluation of Vibrio cholerae O1, Serotype Inaba, Polysaccharide-Cholera Toxin Conjugates in Adult Volunteers. Infect. Immun. 66: 3095-3099 [Abstract] [Full Text]